PreludeDx Enters into Preferred Provider Agreement with Three Rivers Provider Network for its Novel DCIS test, DCISionRT

Agreement with TRPN Provides Access to 200 Million Patients Across 4.3 Million Provider Locations LAGUNA HILLS, Calif., August 2, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today...

Click to view original post